---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046124"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:17:29.579773+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M

## Summary
- Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.
- Net loss $11.3M vs $5.7M; operating loss $10.5M (prior-year included $7.6M asset sale gain).
- Cash $42.8M; reiterates FY2025 revenue guidance $85-88M (23-27% growth), opEx flat YoY.
- Full U.S. launch of larger OviTex PRS for plastic/reconstructive surgery commenced.

## SEC filing metadata
- accession: 0001104659-25-046124
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/0001104659-25-046124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/tm2514412d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046124
- JSON: https://secwatch.observer/filing/0001104659-25-046124.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.